Teva Unveils Generic Lunesta Tablets in US

Teva Pharmaceutical Industries Ltd. TEVA announces the launch of the generic equivalent to Lunesta® (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States. Lunesta® Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!